Hongtao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongtao Liu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Guina Liu
Department of Ophthalmology West China
1 shared publication- Guina Liu
Sichuan University
1 shared publication - Guojiao Song
Beijing Tongren Eye Center, Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
1 shared publication - Hanqing Zhao
Beijing Tongren Eye Center, Beijing key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
1 shared publication - Siqi Wang
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China
1 shared publication Wei Xu
Department of Ophthalmology West China
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (10) , 833
Three-dimensional rendering of optical coherence tomography for a vitreous cyst: moving beyond cross-sectional interpretation
Three-dimensional rendering of optical coherence tomography for a vitreous cyst: moving beyond cross-sectional interpretation
- 1 October 2026
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 16 (10) , 833
Open AccessThree-dimensional rendering of optical coherence tomography for a vitreous cyst: moving beyond cross-sectional interpretation
Three-dimensional rendering of optical coherence tomography for a vitreous cyst: moving beyond cross-sectional interpretation
- Open Access
- 30 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7598
Reported Retinal Detachment in Anti-VEGF-Treated Retinopathy of Prematurity: A Systematic Review and Meta-Analysis
Objectives: To estimate the incidence of reported retinal detachment (RD) after primary anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP) and to explore study-level factors associated with RD incidence. Methods: PubMed, EMBASE, Cochrane Library, and Web of Science were searched up to 24 May 2026, for English-language studies reporting RD outcomes after anti-VEGF monotherapy for ROP. Pooled incidence was estimated with a random-effects model using Freeman–Tukey double arcsine transformation. Heterogeneity, subgroup differences, publication bias, and leave-one-out sensitivity were assessed. Results: Twenty-seven studies (5598 eyes; 135 RD events) were included, comprising twelve case series, thirteen cohort studies, and two randomized controlled trials; thus, the evidence was predominantly retrospective. The pooled RD incidence was 1.4% (95% CI, 0.5–2.7%; I2 = 80.8%). The estimate remained stable on leave-one-out sensitivity analysis; the exclusion of Tong et al. markedly reduced heterogeneity. Higher RD incidence was observed in Asian studies, single-center studies, and studies with predominantly Zone I ROP or aggressive ROP (AROP). Incidence varied by postmenstrual age at treatment, gestational age, birth weight, and anti-VEGF agent. No significant publication bias was detected. Conclusions: RD after primary anti-VEGF therapy for ROP is uncommon but sight-threatening, with higher incidence associated with greater disease severity and postmenstrual age. Prolonged, risk-stratified follow-up is warranted for infants with Zone I or AROP. Standardized RD definitions, subtype classification, and severity-adjusted prospective comparisons are needed.
- 30 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7598
Open AccessReported Retinal Detachment in Anti-VEGF-Treated Retinopathy of Prematurity: A Systematic Review and Meta-Analysis
Objectives: To estimate the incidence of reported retinal detachment (RD) after primary anti-vascular endothelial growth factor (anti-VEGF) treatment for retinopathy of prematurity (ROP) and to explore study-level factors associated with RD incidence. Methods: PubMed, EMBASE, Cochrane Library, and Web of Science were searched up to 24 May 2026, for English-language studies reporting RD outcomes after anti-VEGF monotherapy for ROP. Pooled incidence was estimated with a random-effects model using Freeman–Tukey double arcsine transformation. Heterogeneity, subgroup differences, publication bias, and leave-one-out sensitivity were assessed. Results: Twenty-seven studies (5598 eyes; 135 RD events) were included, comprising twelve case series, thirteen cohort studies, and two randomized controlled trials; thus, the evidence was predominantly retrospective. The pooled RD incidence was 1.4% (95% CI, 0.5–2.7%; I2 = 80.8%). The estimate remained stable on leave-one-out sensitivity analysis; the exclusion of Tong et al. markedly reduced heterogeneity. Higher RD incidence was observed in Asian studies, single-center studies, and studies with predominantly Zone I ROP or aggressive ROP (AROP). Incidence varied by postmenstrual age at treatment, gestational age, birth weight, and anti-VEGF agent. No significant publication bias was detected. Conclusions: RD after primary anti-VEGF therapy for ROP is uncommon but sight-threatening, with higher incidence associated with greater disease severity and postmenstrual age. Prolonged, risk-stratified follow-up is warranted for infants with Zone I or AROP. Standardized RD definitions, subtype classification, and severity-adjusted prospective comparisons are needed.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
Pharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies
Diabetic macular edema (DME) remains a leading cause of vision loss in the working-age population, yet its management is undergoing a fundamental paradigm shift from high-frequency anti-VEGF monotherapy toward more durable and multi-mechanism therapeutic strategies. This narrative review provides an up-to-date overview of the pharmacological landscape of DME as of 2025, synthesizing evidence from pivotal clinical trials, recent regulatory approvals, and available real-world outcomes. We examine the transition toward injection-sparing approaches and discuss the clinical rationale for targeting alternative biological pathways beyond VEGF inhibition, including angiopoietin-2 (eg, faricimab), the plasma kallikrein-kinin system, and tyrosine kinase-mediated signaling. Collectively, emerging evidence suggests that the future management of DME will be defined by a paradigm shift toward injection-sparing, multi-pathway therapeutic strategies, extending beyond short-term fluid suppression toward a more personalized, precision-medicine framework that prioritizes long-term durability, safety, and functional outcomes.
- 1 February 2026
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 20, 1-16
Open AccessPharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies
Diabetic macular edema (DME) remains a leading cause of vision loss in the working-age population, yet its management is undergoing a fundamental paradigm shift from high-frequency anti-VEGF monotherapy toward more durable and multi-mechanism therapeutic strategies. This narrative review provides an up-to-date overview of the pharmacological landscape of DME as of 2025, synthesizing evidence from pivotal clinical trials, recent regulatory approvals, and available real-world outcomes. We examine the transition toward injection-sparing approaches and discuss the clinical rationale for targeting alternative biological pathways beyond VEGF inhibition, including angiopoietin-2 (eg, faricimab), the plasma kallikrein-kinin system, and tyrosine kinase-mediated signaling. Collectively, emerging evidence suggests that the future management of DME will be defined by a paradigm shift toward injection-sparing, multi-pathway therapeutic strategies, extending beyond short-term fluid suppression toward a more personalized, precision-medicine framework that prioritizes long-term durability, safety, and functional outcomes.